請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19787
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊偉勛(Wei-Shiung Yang) | |
dc.contributor.author | Chun-Yih Hsieh | en |
dc.contributor.author | 謝君儀 | zh_TW |
dc.date.accessioned | 2021-06-08T02:19:08Z | - |
dc.date.copyright | 2020-09-16 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-08-19 | |
dc.identifier.citation | Abella V, Scotece M, Conde J, Gomez R, Lois A, Pino J, Gomez-Reino JJ, Lago F, Mobasheri A, Gualillo O. The potential of lipocalin-2/NGAL as biomarker for inflammatory and metabolic diseases. Biomarkers. 2015 Adapala VJ, Buhman KK, Ajuwon KM. Novel anti-inflammatory role of SLPI in adipose tissue and its regulation by high fat diet. J Inflamm (Lond). 2011 Feb 28. Alvarez-Llamas G, Szalowska E, de Vries MP, Weening D, Landman K, Hoek A, Wolffenbuttel BH, Roelofsen H, Vonk RJ. Characterization of the human visceral adipose tissue secretome. Mol Cell Proteomics. 2007 Apr. American Diabetes A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011 Jan. Ariza X, Graupera I, Coll M, Sola E, Barreto R, Garcia E, Moreira R, Elia C, Morales-Ruiz M, Llopis M, et al. Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. J Hepatol. 2016 Jul. Brohee S, van Helden J. Evaluation of clustering algorithms for protein-protein interaction networks. BMC Bioinformatics. 2006 Nov 6. Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014 Cornelius P, MacDougald OA, Lane MD. Regulation of adipocyte development. Annu Rev Nutr. 1994 Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 2018 Oct 1. da Luz PL, Favarato D, Faria-Neto JR, Jr., Lemos P, Chagas AC. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics (Sao Paulo). 2008 Aug. Dai L, Golembiewska E, Lindholm B, Stenvinkel P. End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes. Contrib Nephrol. 2017 Doshi M, Streja E, Rhee CM, Park J, Ravel VA, Soohoo M, Moradi H, Lau WL, Mehrotra R, Kuttykrishnan S, et al. Examining the robustness of the obesity paradox in maintenance hemodialysis patients: a marginal structural model analysis. Nephrol Dial Transplant. 2016 Aug. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: a review. Mediators Inflamm. 2010 Funcke JB, Scherer PE. Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J Lipid Res. 2019 Oct. Grassmann S, Wirsching J, Eichelmann F, Aleksandrova K. Association Between Peripheral Adipokines and Inflammation Markers: A Systematic Review and Meta-Analysis. Obesity (Silver Spring). 2017 Oct. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25. Haku S, Wakui H, Azushima K, Haruhara K, Kinguchi S, Ohki K, Uneda K, Kobayashi R, Matsuda M, Yamaji T, et al. Early Enhanced Leucine-Rich alpha-2-Glycoprotein-1 Expression in Glomerular Endothelial Cells of Type 2 Diabetic Nephropathy Model Mice. Biomed Res Int. 2018 Han MS, White A, Perry RJ, Camporez JP, Hidalgo J, Shulman GI, Davis RJ. Regulation of adipose tissue inflammation by interleukin 6. Proc Natl Acad Sci U S A. 2020 Feb 11. Hoggard N, Cruickshank M, Moar KM, Bashir S, Mayer CD. Using gene expression to predict differences in the secretome of human omental vs. subcutaneous adipose tissue. Obesity (Silver Spring). 2012 Jun. Hong Q, Zhang L, Fu J, Verghese DA, Chauhan K, Nadkarni GN, Li Z, Ju W, Kretzler M, Cai GY, et al. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-beta-Induced Angiogenesis. J Am Soc Nephrol. 2019 Apr. Hwang LC, Bai CH, Sun CA, Chen CJ. Prevalence of metabolically healthy obesity and its impacts on incidences of hypertension, diabetes and the metabolic syndrome in Taiwan. Asia Pac J Clin Nutr. 2012 Imamaki H, Ishii A, Yokoi H, Kasahara M, Kuwabara T, Mori KP, Kato Y, Kuwahara T, Satoh M, Nakatani K, et al. Low Serum Neutrophil Gelatinase-associated Lipocalin Level as a Marker of Malnutrition in Maintenance Hemodialysis Patients. PLoS One. 2015 Jager J, Gremeaux T, Cormont M, Le Marchand-Brustel Y, Tanti JF. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology. 2007 Jan. Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017 May. Kang SM, Yoon JW, Ahn HY, Kim SY, Lee KH, Shin H, Choi SH, Park KS, Jang HC, Lim S. Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS One. 2011 Kaul S, Rothney M, Peters D, Wacker W, Landberg C, Shapiro M, Ergun D. Dual-Energy X-Ray Absorptiometry for Quantification of Visceral Fat. Obesity (Silver Spring, Md.). 2012 01/26. Kittiskulnam P, Johansen KL. The obesity paradox: A further consideration in dialysis patients. Semin Dial. 2019 Nov. Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2012 Jan. Liu C, Wang J, Wei Y, Zhang W, Geng M, Yuan Y, Chen Y, Sun Y, Chen H, Zhang Y, et al. Fat-Specific Knockout of Mecp2 Upregulates Slpi to Reduce Obesity by Enhancing Browning. Diabetes. 2020 Jan. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul. McNally B, Robb R, Mehta M, Vellano K, Valderrama AL, Yoon PW, Sasson C, Crouch A, Perez AB, Merritt R, et al. Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--December 31, 2010. MMWR Surveill Summ. 2011 Jul 29. Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020 Feb 11. Mechanick JI, Zhao S, Garvey WT. The Adipokine-Cardiovascular-Lifestyle Network: Translation to Clinical Practice. J Am Coll Cardiol. 2016 Oct 18. Moschen AR, Adolph TE, Gerner RR, Wieser V, Tilg H. Lipocalin-2: A Master Mediator of Intestinal and Metabolic Inflammation. Trends Endocrinol Metab. 2017 May. Musi N, Guardado-Mendoza R. Chapter 14 - Adipose Tissue as an Endocrine Organ. 2014 Mutch DM, Rouault C, Keophiphath M, Lacasa D, Clement K. Using gene expression to predict the secretome of differentiating human preadipocytes. Int J Obes (Lond). 2009 Mar. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, American Diabetes A. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care. 2007 Mar. Pan WH, Chang HY, Yeh WT, Hsiao SY, Hung YT. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993-1996. J Hum Hypertens. 2001 Nov. Pek SL, Tavintharan S, Wang X, Lim SC, Woon K, Yeoh LY, Ng X, Liu J, Sum CF. Elevation of a novel angiogenic factor, leucine-rich-alpha2-glycoprotein (LRG1), is associated with arterial stiffness, endothelial dysfunction, and peripheral arterial disease in patients with type 2 diabetes. J Clin Endocrinol Metab. 2015 Apr. Pek SLT, Cheng AKS, Lin MX, Wong MS, Chan EZL, Moh AMC, Sum CF, Lim SC, Tavintharan S. Association of circulating proinflammatory marker, leucine-rich-alpha2-glycoprotein (LRG1), following metabolic/bariatric surgery. Diabetes Metab Res Rev. 2018 Oct. Petak S, Barbu CG, Yu EW, Fielding R, Mulligan K, Sabowitz B, Wu CH, Shepherd JA. The Official Positions of the International Society for Clinical Densitometry: body composition analysis reporting. J Clin Densitom. 2013 Oct-Dec. Shepherd JA, Baim S, Bilezikian JP, Schousboe JT. Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on Body Composition. J Clin Densitom. 2013 Oct-Dec. Stefan N, Schick F, Haring HU. Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans. Cell Metab. 2017 Aug 1. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017 Jan 4. Wang X, Abraham S, McKenzie JAG, Jeffs N, Swire M, Tripathi VB, Luhmann UFO, Lange CAK, Zhai Z, Arthur HM, et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature. 2013 Jul 18. Yajima T, Arao M, Yajima K, Takahashi H, Yasuda K. The associations of fat tissue and muscle mass indices with all-cause mortality in patients undergoing hemodialysis. PLoS One. 2019 Yang FJ, Hsieh CY, Shu KH, Chen IY, Pan SY, Chuang YF, Chiu YL, Yang WS. Plasma Leucine-Rich alpha-2-Glycoprotein 1 Predicts Cardiovascular Disease Risk in End-Stage Renal Disease. Sci Rep. 2020 Apr 6. 潘文涵, 陳信任, 張新儀, 莊紹源, 潘文涵, 林偉婷, 李建宏, Tsai T-L, Kuo C-C, Chung Y-T, et al. 國民營養健康狀況變遷調查. 2016 衛生福利部國民健康署,台灣肥胖醫學會,考科藍臺灣研究中心. 成人肥胖防治實證指引 Evidences-based guideline on adult obesiy prevent and management. 2018 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/19787 | - |
dc.description.abstract | 台灣肥胖的盛行率在過去20年間逐漸增加,伴隨著人口高齡化,肥胖成為孕育代謝疾病,如糖尿病、代謝症候群、非酒精性脂肪肝、慢性腎病,心血管疾病與多項癌症之溫床。當身體處於營養或能量過剩之狀態,脂肪組織所出現的變化包括脂肪細胞肥大,巨噬細胞浸潤增加且轉為以M1分類占上風。脂肪組織除了負責以三酸甘油脂之形式儲存身體過剩的營養外,也是一個具有內分泌功能的器官,透過分泌游離脂肪酸及多種脂肪激素,而可影響脂肪組織自身及其他負責能量攝取或代謝之器官,如下視丘、肝臟、骨骼肌等,藉此以維持身體能量的恆定。肥胖時,脂肪組織及脂肪細胞發生上述變化時,脂肪激素之分泌也隨之改變。 本研究利用小鼠3T3-L1前脂肪細胞培養,引導其分化為成熟脂肪細胞後,加入IL-1β引發脂肪細胞之發炎及胰島素阻抗作為模擬脂肪細胞發炎之模型。加入IL-1β之脂肪細胞作為實驗組及未做處理之細胞作為對照組,兩組細胞以微陣列實驗檢驗基因表現,並分析兩組間基因表現之差異。相較對照組,在實驗組中基因表現顯著上升並達六倍以上之44個基因,被挑選為脂肪發炎生物指標之候選者。這些候選基因之表現利用定量即時聚合酶鏈鎖反應加以驗證,而排除2個相對表現量在實驗中並未顯著上升之基因。 候選的42個基因利用STRING資料庫加以分析建立一蛋白質-蛋白質關係之網路。此網路中有267對蛋白質-蛋白質關聯,其中以防禦機轉、細胞激素、發炎反應、化學趨向之路徑聚集最為顯著,而兩條與脂質相關之路徑也呈現基因顯著集中之現象。LCN2及SLPI出現於脂質相關途徑,且皆與重要的脂肪激素IL-6間有中度的關聯性,而另一基因LRG1,與上述LCN2及SLPI皆在STRING資料庫預測有相關性。在K-means群聚分析中,SLPI及LRG1持續出現於同一亞群。因此,本研究挑選LCN2(其蛋白質產物為NGAL),SLPI及LRG1為有潛力之生物指標,可作為脂肪發炎之代表,並藉由兩不同特色的臨床群組,進一步探討此三指標之臨床意義。 第一個臨床案例群組共收案175位女性受試者,他們皆無心血管疾病或糖尿病。這群女性受試者於收案時接受健康史調查,血糖血脂等代謝指標檢驗,包括75克葡萄糖耐受試驗。此外他們亦接受雙能量X光吸光式測定儀測定身體組成。此小群之研究目的為檢驗脂肪細胞所衍生之指標與代謝異常及身體組成之相關性。在這個群組中,超過半數女性腰圍超過80公分之標準,17.1%受試者達到糖尿病之診斷標準,27.4%和代謝症候群。這個橫斷性的研究顯示,不同的代謝異常中身體組成之型態其實有個別特徵。在肥胖或中心肥胖者,全身脂肪量皆同步增加,而在代謝症候群或胰島素阻抗者,脂肪增加只發生於上臂及中心區域。在三個脂肪細胞指標中,NGAL與肥胖,中心肥胖及異常的葡萄糖代謝,如糖尿病及胰島素阻抗皆呈顯著相關。NGAL亦與全身的脂肪量以及脂肪中心分佈之型態呈現正相關。再者,本群組中有140位女性之身體質量指數並不超過27 kg/m2,根據2017年提出的代謝風險診斷標準,將這群未達肥胖標準的女性,區分為代謝健康及代謝不健康兩組。此診斷標準之核心在除了葡萄糖,血壓,血脂代謝異常之外,加入胰島素阻抗以及隱性發炎兩項,及排除代謝症候群的腰圍標準。在這群未達肥胖的女性中,代謝不健康者亦有特有之身體組成分佈。當與健康者相比,不健康者雖有較高的身體質量指數,但其下肢與骨盆區域之肥肉瘦肉組織量皆未隨之增加;更重要的是不健康者之脂肪中心分佈程度與肥胖者並無顯著差異,顯示未達肥胖但代謝病不健康者其脂肪分布特別集中於身體中央,而在周邊部位未見增加。而在代謝不健康的非肥胖女性,SLPI呈現顯著的增加,且此關聯不受年紀或中心肥胖之影響。 第二群臨床案例探討末期腎病接受慢性血液透析治療的169為患者,其中45.3%患有糖尿病。這群患者自2016年4月收案並接受追蹤至2019年10月。於收案時,患者接受過去病史詢問,生化血液檢驗及脂肪細胞指標。橫斷式分析顯示LRG1與患者罹有周邊動脈疾病及缺血性中風有顯著相關,且LRG1對周邊動脈疾病在調整共病因子後仍呈正相關。而三項脂肪細胞指標與患者之身體質量指數或代謝指標皆無關聯。38個月的追蹤期間中,34位患者死亡,14位歸因於心血管疾病,其餘20位歸因於非心血管疾病包括腸胃道出血,肝臟疾病及感染。在這群末期腎病患者中,收案時較高齡,較低的血紅素與白蛋白,較高的鹼性磷酸酶及肝指數,罹有糖尿病,冠狀動脈疾病,週邊動脈疾病,缺血性中風,冠狀動脈繞道手術,癌症及肝硬化皆與較高的死亡風險相關。而脂肪指標中,LRG1與總體死亡風險呈現正相關,SLPI及NGAL則與死亡風險呈現負相關。而將死亡區分為心血管事件及非心血管事件兩類後,心血管事件並未與任一脂肪細胞指標有相關,顯示前述橫斷性研究LRG1與大血管疾病之相關性並未影響患者之存活。而針對非心血管事件造成之死亡,三個指標皆與死亡風險呈現與前述總體死亡率相同之趨勢。而在校正影響死亡的共病因子之後,唯有SLPI與較低的死亡率仍保有顯著的相關性。 本研究利用模擬脂肪細胞發炎的細胞模型,以微陣列實驗分析脂肪細胞發炎所誘發之基因表現差異後,挑選出轉錄顯著上升超過6倍之基因後,將候選基因利用STRING資料庫建成蛋白質關聯之網路,挑選出有潛力作為脂肪細胞發炎指標之三個基因。臨床分析顯示不同的代謝異常其身體組成及生物指標之表現皆有個別特色,因此在面對肥胖等代謝疾病,體內所存在之全身性發炎及多重器官影響,本研究利用系統生物學工具來分析疾病表現以篩選診斷甚或診斷的標的,在未來疾病的診治必定會扮演更要的角色。而在本研究所發現生物指標與不同代謝表現型之相關,該指標是否參與代謝異常之病生理機轉及是否能監測疾病程度或預後的指標,有賴後續之追蹤。 | zh_TW |
dc.description.abstract | Metabolic health is closely linked with risk of cardiovascular disease, diabetes mellitus (DM), metabolic syndrome (MS) and many types of cancers. The morbidity and mortality associated with obesity pose a significant burden on public health. Body fat excess is characterized by adipocyte inflammation and an altered adipokine profile. Adipose hypertrophy, increased infiltration of macrophages and switch to M1 phenotype, and secretion of proinflammatory cytokines contribute to development of insulin resistance and long-term cardiometabolic complications. Adipokines released by adipocytes and macrophages in the stromal vascular fraction of adipose tissue can affect adipose tissue per se as well as distant effect organs. Obesity is characterized by increase in IL-6, TNF-α, IL-1, resistin and a reduction of adiponectin. Obesity is most commonly defined by excess body mass index (BMI) and assessment of metabolic health will also include measurement of body composition, along with parameters of lipid and glucose metabolism. Investigation of adipokines in different metabolic traits may provide diagnostic and interventional clues and adoption of systems approach may provide better overview of adipose inflammation in dealing with a complex, multi-system alteration triggered by obesity. Mouse 3T3-L1 preadipocyte is a well-established model for studying adipogenesis. 3T3-L1 preadipocyte was induced to differentiated adipocytes, and was treated with IL-1β 40 mg/ml for 24 hours to induce insulin resistance and inflammation in vitro. The cultured adipocytes with and without IL-1β treatment were submitted for Affymetrix GeneChip Mouse Genome 430 2.0 microarray analysis. There were 42 genes upregulated by more than 6-fold and adiponectin expression was reduced by 50% in the IL-1β treated adipocytes. Validation with real-time qPCR was performed. STRING database was employed to created protein-protein interaction network and enriched pathways were reviewed to provide insights of the molecular functions of our candidate genes. Three candidate genes, leucine-rich alpha-2 glycoprotein 1 (LRG1), secretory leukocyte peptidase inhibitor (SLPI), and neutrophil gelatinase-associated lipocalin (NGAL) encoded by LCN2 were not a part of well-recognized inflammatory and chemotactic pathways. They were selected as potential novel biomarkers and further investigation was performed to explore their association with metabolic health and inflammation. One clinical cohort enrolled 175 women aged 37 to 67 years who did not have established cardiovascular disease. Body composition was assessed by dual energy X-ray absorptiometry (DXA) and biochemical assay and adipocyte biomarkers were measured. We found out that obesity and central obesity were characterized by a general increase in body fat, while in MS and insulin resistance, fat gain only occurred in arms and central regions. NGAL was positively correlated with the size of total and central fat depots, as well as obesity and central obesity phenotypes. NGAL was also associated with dysregulated glucose metabolism, and the presence of DM and insulin resistance. Among 140 women with BMI < 27 kg/m2, 50 of them had 2 or more components of metabolic risk criteria and were categorized as metabolically obese non-obese (MONO) phenotype. The components of metabolic risk criteria included MS criteria except central obesity and inclusion of insulin resistance and subclinical inflammation. Serum ferritin was used as a surrogate marker of inflammation. MONO women had a comparable degree of central adiposity to those with BM ≥ 27 kg/m2. One of the features unique to MONO was the lack of expansion of fat and lean mass in leg and gynoid region. SLPI was found to be an independent risk factor for metabolically unhealthy status in non-obese women after adjusting for age and android-gynoid fat mass ratio. End-stage renal disease (ESRD) is characterized by chronic inflammation. The second cohort enrolled 169 ESRD patients treated with hemodialysis, including 77 diabetics (45.3%). BMI was available in 134 patients at baseline and 16.4% of them were obese. Comorbid conditions including coronary artery disease (CAD), heart failure, ischemic stroke, peripheral artery disease (PAD), liver cirrhosis, and malignancy were recorded at baseline. The patients were followed from April, 2016 until death or study end in October, 2019 At baseline, higher LRG1 was associated with increased frequency of PAD and ischemic stroke. The correlation of LRG1 with PAD remained significant after multivariate adjustment. The biomarkers were not correlated with obesity. We further investigate if adipocyte-derived biomarkers were associated with patient survival. The mean follow-up duration was 1142.65 ± 305.52 days. Thirty-four patients (20.1%) expired, 14 patients died of cardiovascular events, including 4 out-of-hospital cardiac arrests (OHCA). Lower baseline SLPI and NGAL levels were associated with better overall survival and inverse relationship was observed for LRG1. Mortality was further divided into cardiovascular and non- cardiovascular causes. Cox-regression analysis showed higher LRG1, lower SLPI and lower NGAL were associated with poor non-cardiac survival, identical to the trend of all-cause mortality. After adjusting for age, albumin, hemoglobin, and key comorbidities, baseline lower SLPI and NGAL levels were predictive better all-cause mortality. By transcriptomic analysis of cultured adipocyte treated with IL-1β, we identified three markers associated with adipose inflammation. In the cohort of otherwise healthy women, circulating NGAL levels were proportional to total and central adiposity as well abnormal glucose metabolism. SLPI was associated with another aspect of metabolic health; it was linked with metabolic unhealthy state and subclinical inflammation rather than fatness or insulin resistance. In the second cohort of hemodialysis patients, there was no association between biomarkers and BMI or lipid profiles. LRG1 was correlated with inflammatory markers, CRP and IL-6, as well as increased prevalence of PAD, but this was not translated to cardiovascular mortality. Lower SLPI and NGAL were associated with better overall survival, which may be explained by reduced non-cardiac mortality risk. In this study, we demonstrated the effectiveness of transcriptome profiling by microarray in combination with network analysis. Three biomarkers, NGAL, SLPI, LRG1, reflecting different aspects of metabolic health were identified and they may be employed in further disease phenotyping or risk stratification in metabolic disorders. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T02:19:08Z (GMT). No. of bitstreams: 1 U0001-1408202017121600.pdf: 2963552 bytes, checksum: 8e6e058522b4db9422a279b520112a2b (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | Table of Contents Authorization of Dissertation Committee…………………………………………….i Acknowledgement……………………………………………………………………...ii Abstract (Chinese)……………………………………………………………………..iii Abstract………………………………………………………………………………...vi Table of Contents……………………………………………………………………….x Main Content of Doctoral Dissertation Chapter 1. Introduction………………………………………………………………..1 1.1 Adipose inflammation and altered adipokine secretion are the link between obesity and metabolic health………………………………………………………1 1.2 Chronic inflammation in obesity and renal failure………………………………4 1.3 Systems biology approach in the search of novel adipokines……………………4 Chapter 2 Subjects, materials and methods…………………………………………..6 2.1 3T3-L1 preadipocyte culture and induction of differentiation into adipocytes...6 2.2 Identification of genes upregulated by IL-1β treatment in 3T3-L1 adipocytes…7 2.2.1 RNA extraction, reverse transcription (RT), RT-polymerase chain reaction (PCR), and microarray analysis……………………………………………………….7 2.2.2 Real-time PCR validation of gene upregulation in IL-1β treated adipocytes…7 2.2.3 Statistical analysis for the PCR experiments……………………………………8 2.2.4 Network construction and pathway analysis of upregulated genes associated with adipose inflammation……………………………………………………………..8 2.3 Collection of two clinical cohort characterized by chronic inflammation……...9 2.3.1 A cohort of apparently healthy women with and body composition assessment and metabolic evaluation………………………………………………………………9 2.3.1.1 Data collection and laboratory examinations…………………………………9 2.3.1.2 Body composition measurements with dual energy X-ray absorptiometry (DXA)…………………………………………………………………………………..10 2.3.1.3 The definition of metabolic disorders………………………………………...11 2.3.1.4 Statistical analysis……………………………………………………………..12 2.3.2 A cohort of adult end-stage renal disease (ESRD) patients treated with hemodialysis…………………………………………………………………………...13 2.3.2.1 Data collection and laboratory exams……………………………………….14 2.3.2.2 Patient characteristics and definition of CV co-morbidities………………...14 2.3.2.3 Follow-up and analysis of association between mortality with baseline characteristics…………………………………………………………………………15 2.3.2.4 Statistical analysis…………………………………………………………….15 Chapter 3 Results……………………………………………………………………...16 3.1 Differentially expressed genes in IL-1β treated 3T3-L1 adipocytes……………16 3.2 Selection and validation of potential biomarkers associated with adipose inflammation from protein-protein interaction (PPI) network……………………16 3.3 Clinical associations of biomarkers with body fat distribution and metabolic health in female without established CV disease……………………………………19 3.3.1 Body composition and metabolic profile in apparently healthy female……..19 3.3.2 The association of adipocyte biomarkers with body composition and metabolic phenotypes in apparently healthy female……………………………………………23 3.3.3 The association of biomarkers with body composition and metabolic health in non-obese women (BMI < 27 kg/m2)………………………………………………….24 3.4 Clinical implications of biomarkers derived from adipose inflammation in end-stage renal disease (ESRD)……………………………………………………………27 3.4.1 Baseline demographics and clinical characteristics of ESRD patients……….27 3.4.2 The association of baseline adipocyte biomarkers with mortality in ESRD patients…………………………………………………………………………………29 Chapter 4 Discussion…………………………………………………………………..30 4.1 Biomarker discovery by construction of protein-protein interaction (PPI) network and pathway analysis in IL-1β treated 3T3-L1 adipocytes………………30 4.2 Different metabolic phenotypes are characterized by specific body composition……………………………………………………………………………31 4.3 Adipokines reflect different aspects of metabolic health and patterns of body composition……………………………………………………………………………33 4.4 The role of biomarkers associated with adipose inflammation in ESRD patients treated with hemodialysis…………………………………………………………….36 4.5 Future perspectives……………………………………………………………….38 References……………………………………………………………………………..41 Tables…………………………………………………………………………………..47 Table 1. List of primers and probes of key genes used for reverse transcription (RT)-polymerase chain reaction (PCR) and real-time PCR………………………..47 Table 2. Demographics and body composition in normal weight (BMI < 24 kg/m2), overweight (24 ≤ BMI < 27 kg/m2), and obese (BMI ≥ 27 kg/m2) women…………48 Table 3. Clinical characteristics, glucose tolerance status and insulin sensitivity in normal, overweight, and obese women………………………………………………51 Table 4. Comparisons of biochemical data and adipocyte biomarkers in normal, overweight, and obese women………………………………………………………..53 Table 5. Demographics and body composition in women with or without MS…..55 Table 6. Clinical characteristics, glucose tolerance and insulin resistant status in women with or without MS…………………………………………………………..57 Table 7. Comparisons of biochemical data and adipocyte biomarkers in women with or without MS……………………………………………………………………58 Table 8. Demographics and body composition in women with or without DM…...59 Table 9. Clinical characteristics and metabolic disorders in women with or without DM……………………………………………………………………………………..61 Table 10. Comparisons of biochemical data and adipocyte biomarkers in women with or without DM…………………………………………………………………...62 Table 11. Demographics and body composition in women with or without central obesity (CO)……………………………………………………………………………63 Table 12. Clinical characteristics, glucose tolerance status and metabolic disorder in women with or without central obesity (CO)……………………………………..65 Table 13. Comparisons of biochemical data and adipocyte biomarkers in women with or without central obesity (CO)………………………………………………...66 Table 14. Demographics and body composition of women with or without insulin resistance (HOMA-IR > 2.5)………………………………………………………….67 Table 15. Clinical characteristics, metabolic disorders, and obesity in women with or without insulin resistance (HOMA-IR > 2.5)…………………………………….69 Table 16. Comparisons of biochemical data and adipocyte biomarkers in women with or without insulin resistance (HOMA-IR > 2.5)……………………………….70 Table 17. Demographics and body composition in metabolically healthy non-obese (MHNO), metabolically obese non-obese (MONO), and obese women……………71 Table 18. Clinical characteristics and metabolic disorders in MHNO, MONO, and obese women…………………………………………………………………………..74 Table 19. Biochemical data and adipocyte biomarkers in MHNO, MONO, and obese women…………………………………………………………………………..75 Table 20. Baseline characteristics and comorbidities in end-stage renal disease (ESRD) patients with or without DM………………………………………………..77 Table 21. Blood biochemistry, pro-inflammatory cytokines, and adipocyte-derived biomarkers in ESRD patients with or without DM…………………………………78 Table 22. Hemogram in ESRD patients with or without DM……………………...80 Table 23. Univariate and multivariate logistic regression on the frequency of peripheral artery disease (PAD) in ESRD patients…………………………………81 Table 24. Univariate and multivariate logistic regression on the frequency of ischemic stroke in ESRD patients……………………………………………………82 Table 25. Cause of death (COD) in ESRD patients treated with hemodialysis over 38-month study period………………………………………………………………..82 Table 26. Univariate and multivariate Cox regression analysis on all-cause mortality in ESRD patients treated with hemodialysis…………………………….83 Figures…………………………………………………………………………………84 Figure 1. Validation of gene upregulation in IL-1β treated 3T3-L1 adipocytes by real-time qPCR………………………………………………………………………..84 Figure 2. Real-time qPCR experiment showed upregulation of LRG1 and down-regulation of ADIPOQ in IL-1β treated 3T3-L1 adipocytes compared to control………………………………………………………………………………….84 Figure 3. Network of protein-protein interactions constructed by STRING formed by 42 upregulated genes in 3T3-L1 adipocytes treated with IL-1β………………..85 Figure 4. Lipid-related pathways in the network composed of upregulated genes associated with adipose inflammation………………………………………………86 Figure 5. K-means clustering of upregulated genes associated with adipose inflammation………………………………………………………………………….87 Figure 6. Co-expression pattern of upregulated genes in 3T3-L1 adipocytes treated with IL-1β……………………………………………………………………………..88 Figure 7. The prevalence of metabolic disorders in women without established cardiovascular (CV) disease (N=175)………………………………………………..89 Figure 8. Evaluation of regional body composition by dual X-ray absorptiometry (DXA) and common parameters of central adiposity derived from anthropometric measures……………………………………………………………………………….89 Figure 9. Characteristics of body composition and biomarker associated with adipose inflammation in different metabolic disorders……………………………..90 Figure 10. The distribution of metabolic health in obese and non-obese women in female without established CV disease (N=175)…………………………………….91 Figure 11. The frequency of metabolic and cardiovascular (CV) disorders in 77 diabetic (45.6%) and 92 non-diabetic (54.4%) hemodialysis patients……………..91 Figure 12. Univariate Cox regression analysis of adipocyte biomarkers (LRG1, SLPI, and NGAL) with cardiovascular (CV) or non-CV survival…………………………92 | |
dc.language.iso | en | |
dc.title | 脂肪細胞發炎之指標於代謝疾病與末期腎病之變化 | zh_TW |
dc.title | The Role of Biomarkers Derived from Adipocyte Inflammation in Metabolic Health and End-stage Renal Disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 陳祈玲(Chi-Ling Chen),阮雪芬(Hsueh-Fen Juan),姜至剛(Chih-Kang Chiang),張明揚(Ming-Yang Chang) | |
dc.subject.keyword | 肥胖,脂肪發炎,脂肪激素,嗜中性白血球明膠酶相關運載蛋白,分泌性白血球蛋白酶抑制蛋白,富亮氨酸重複甲型醣蛋白,末期腎病,血液透析, | zh_TW |
dc.subject.keyword | Adipose inflammation,Obesity,Metabolically unhealthy,Adipokine,Leucine-rich repeat alpha-2 glycoprotein 1 (LRG1),Secretory leukocyte peptidase inhibitor (SLPI),Neutrophil-gelatinase associated lipocalin (NGAL, LCN2),End-stage renal disease, | en |
dc.relation.page | 92 | |
dc.identifier.doi | 10.6342/NTU202003468 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2020-08-20 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 基因體與系統生物學學位學程 | zh_TW |
顯示於系所單位: | 基因體與系統生物學學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1408202017121600.pdf 目前未授權公開取用 | 2.89 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。